GoodRx Holdings, Inc. announced earnings results for the second quarter of 2021. Revenue grew to a record $176.6 million, even while believe the backlog of undiagnosed conditions continued to grow. Net income grew 14% year-over-year to $31.1 million, which was impacted by a $37.3 million tax benefit as well as by stock-based compensation expense of $40.7 million in the quarter, $24 million of which related to the nonrecurring co-CEO grant made at the time of the IPO.